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Abstract: Metabolomics and genomics are two complementary platforms for analyzing an 
organism as they provide information on the phenotype and genotype, respectively. These 
two techniques were applied in the dereplication and identification of bioactive compounds 
from a Streptomyces sp. (SM8) isolated from the sponge Haliclona simulans from Irish 
waters. Streptomyces strain SM8 extracts showed antibacterial and antifungal activity. 
NMR analysis of the active fractions proved that hydroxylated saturated fatty acids were 
the major components present in the antibacterial fractions. Antimycin compounds were 
initially putatively identified in the antifungal fractions using LC-Orbitrap. Their presence 
was later confirmed by comparison to a standard. Genomic analysis of Streptomyces sp. 
SM8 revealed the presence of multiple secondary metabolism gene clusters, including a 
gene cluster for the biosynthesis of the antifungal antimycin family of compounds. The 
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antimycin gene cluster of Streptomyces sp. SM8 was inactivated by disruption of the 
antimycin biosynthesis gene antC. Extracts from this mutant strain showed loss of 
antimycin production and significantly less antifungal activity than the wild-type strain. 
Three butenolides, 4,10-dihydroxy-10-methyl-dodec-2-en-1,4-olide (1), 4,11-dihydroxy-
10-methyl-dodec-2-en-1,4-olide (2), and 4-hydroxy-10-methyl-11-oxo-dodec-2-en-1,4-olide 
(3) that had previously been reported from marine Streptomyces species were also isolated 
from SM8. Comparison of the extracts of Streptomyces strain SM8 and its host sponge,  
H. simulans, using LC-Orbitrap revealed the presence of metabolites common to both extracts, 
providing direct evidence linking sponge metabolites to a specific microbial symbiont. 
Keywords: Streptomyces; Haliclona simulans; metabolomics; antimycin;  
antifungal; butenolide 
 
1. Introduction 
Marine sponges are at the forefront of marine natural product discovery. Being sessile animals, they 
rely mainly on chemical means of defense. Sponges produced 37% of all novel marine natural 
products discovered in 2002 [1]. The latest review showed that sponges accounted for 28.6% of novel 
compound discoveries from marine sources in 2012, excluding those isolated from sponge-associated 
microorganisms [2]. 
Sponges play host to a wide variety of endosymbiotic microorganisms such as bacteria, fungi, yeast, 
dinoflagellates, diatoms and microalgae [3]. Indeed, some of the compounds previously isolated from 
sponges have been proven to be products of their endosymbionts [47]. This is a distinct advantage in 
the search for new drugs as this bypasses the supply problem created by the difficulties in procuring 
sufficient quantities of the desired compounds from marine macroorganisms. In addition, the genome 
of the microorganism, as well as the culture conditions, can be manipulated to optimize the production 
of the preferred metabolite. 
The bacterial communities of Haliclona sponges from across the globe have been studied [811] 
and these show a diverse range of endosymbionts, many of which produce bioactive metabolites. Of 
the 52 bacteria isolated from H. simulans from the Irish Sea, 29 possessed antibiotic activity against at 
least one of the bacterial or fungal test strains [8]. 
A Streptomyces sp., SM8, was isolated from H. simulans collected from Irish waters. Partial 16S 
rRNA sequencing indicated that this strain bore 100% similarity to Streptomyces violascens XSD-115 
and several other Streptomyces species [8]. Other strains of S. violascens have been reported to 
produce antibiotics such as actinomycin D and actinomycin X2 (V) [12] (Figure 1), protease inhibitors 
such as trypsin and chymotrypsin inhibitors [13], and 3ȕ-hydroxysteroid oxidase [14]. 
Metabolomics and genomics are two complementary platforms in systems biology. Genomics 
details the genotype of the organism whereas metabolomics reveals its phenotype. While the former is 
widely established, the latter is a relatively new field that is still evolving as both technology and 
various methodologies are improved and refined [15,16]. Although both platforms are used in natural 
product discovery, relatively few studies have used both approaches. Seipke et al. used a combination 
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of genomics and chemical isolation to characterize antifungal compounds from actinomycetes [17,18] 
and genomic and chemical techniques have also been used to study Salinispora tropica, a marine 
actinomycete, leading to the structural elucidation of salinilactam A and providing a greater depth of 
information on the biosynthetic capabilities of S. tropica [19]. The dual approach of metabolomics and 
genomics was used to analyze SM8 in order to facilitate the identification and isolation of bioactive 
compounds with a particular focus on antifungal metabolites. 
Figure 1. Structures of actinomycin D, actinomycin X2 and salinilactam, isolated from 
strains of Streptomyces. 
 
Metabolomic techniques such as nuclear magnetic resonance (NMR) spectroscopy and liquid 
chromatography-high resolution mass spectrometry (LC-HRMS) were applied in the preliminary 
screening of metabolites produced by Streptomyces strain SM8. These two complementary analytical 
techniques allow the rapid identification of classes of compounds present in the samples as well as the 
putative identification of specific compounds [20,21]. However, although LC-HRMS is extremely 
sensitive and can detect compounds present in very low quantities, there are certain classes of 
compounds that cannot be detected by the mass spectrometer, the reason being that they are unable to 
be ionized. NMR, on the other hand, has no separation step and therefore provides a snapshot of the 
metabolome of the sample. It is less sensitive than MS but is more reproducible and has no 
discrimination in detection depending on the concentration of the sample and the power of the 
spectrometer. Both methods of analysis can be applied in the structural elucidation of compounds. 
Extracts of Streptomyces strain SM8 possessed antifungal and antibacterial activity. The goal of this 
study was to use the dual approach of metabolomics and genomics to analyze Streptomyces strain SM8 
in order to facilitate the identification and isolation of bioactive compounds with a particular focus on 
antifungal metabolites. Metabolomics was further applied in the comparison of the extract of 
Streptomyces strain SM8 with that of its host sponge to determine whether compounds produced by the 
bacteria could be found in the sponge. 
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2. Results and Discussion 
Streptomyces strain SM8, isolated from the sponge H. simulans, was cultured on two types of 
media: oatmeal media (OM-SW) and starch-yeast extract-peptone (SYP-SW) media. The crude 
extracts, prepared by solid phase extraction with Amberlite
®
 XAD-16 resin (Rohm and Haas 
Company, Philadelphia, PA, USA), exhibited activity against Bacillus subtilis, Pseudomonas 
aeruginosa, Candida albicans, C. glabrata, Saccharomyces cerevisiae, Aspergillus fumigatus and 
Kluyveromyces marxianus. 
2.1. Genomic Analysis of Streptomyces Strain SM8 
The genome sequence of Streptomyces strain SM8 was determined by Roche 454 pyrosequencing. 
Following assembly, the draft genomic sequence (Table 1) consisted of 534 contigs with a total size  
of 7.2 Mb in and a GC content of 73%. A total of 6647 protein coding genes were annotated, including 
31 putative non-ribosomal peptide synthetase (NRPS) modules and 25 polyketide synthase (PKS) 
modules were identified in the draft genome in addition to other genes predicted to be involved in the 
biosynthesis of secondary metabolites. The genome sequence is deposited at GenBank with accession 
number PRJNA180938. 
Table 1. Genomic data for Streptomyces strain SM8. 
Genomic data for Streptomyces strain SM8 
Genome size 7.155 Mb 
Contigs 534 
GC content 73% 
Gene count 6722 
Protein coding genes 6647 
RNA genes 75 
NRPS modules 31 
PKS modules 25 
Secondary metabolism gene clusters for the known antifungal metabolites antimycin and candicidin 
(Figure 2) were identified in the Streptomyces SM8 genome. The putative candicidin gene cluster  
was spread over 18 contigs in the assembly, however analysis of the cluster by comparison to  
known polyene PKS clusters confirmed that all the predicted biosynthesis genes were present. The 
antimycin gene cluster was also found to be intact by comparison to the published cluster from 
Streptomyces albus sp. S4 [18]. Other predicted secondary metabolism gene clusters present in the 
Streptomyces SM8 genome include a large NRPS gene cluster, similar to a linear gramicidin 
biosynthesis cluster, encoding a predicted 16 amino acid linear peptide and additional smaller NRPS, 
PKS and hybrid secondary metabolism gene clusters. In addition to the gene clusters for modular PKS 
and NRPS the genome was also found to contain genes and gene clusters predicted to be involved in 
the biosynthesis of terpenes, ribosomally encoded peptide antibiotics and siderophores. 
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Figure 2. Structures of antimycin A1 and candicidin. 
 
2.2. Identification of Bioactive Metabolites from Streptomyces Strain SM8 
2.2.1. Chemical Analysis of Antibacterial and Antifungal Fractions from Small-Scale SM8 Extract 
Crude extract, prepared by solid phase extraction with Amberlite
®
 XAD-16 resin (Rohm and Haas 
Company, Philadelphia, PA, USA), from batch cultures of Streptomyces strain SM8 was fractionated 
with water and methanol using reverse phase medium pressure liquid chromatography (MPLC). 
Fractions were assessed for antimicrobial activities against C. albicans and B. subtilis, the fungal and 
bacterial strains that were most sensitive to the crude extract. The minimum inhibitory concentrations 
(MICs) of the most active fractions are shown in Table 2. 
Table 2. MICs of the most active fractions from the SM8 extract. 
Pooled Fraction Yield (mg) B. subtilis MIC (ȝg·mLí1) C. albicans MIC (ȝg·mLí1) 
221226 6.5 7.42 240 
227230 9.5 9.40 210 
239242 9.1 400 80 
243248 13.0 400 90 
HRESIMS data of the semi-purified fractions 221230 revealed the occurrence of two major 
inseparable components with ion peaks at m/z 375.2757/417.3228 [M í H]í in negative mode and  
m/z 377.2898/419.3668 [M í H]+ in positive mode with the molecular formulas of C20H40O6 and 
C23H46O6, respectively. Both ion peaks designated with RDB of 1.0 indicated the aliphatic and 
polyhydroxylated lipid nature of the structure. The 
1
H NMR spectrum in DMSO-d6 exhibited that the 
major compounds in the antibacterial fractions were indeed polyhydroxylated saturated fatty acids. 
Peaks belonging to terminal methyl groups (įH 0.80 to 1.00), aliphatic CH2 groups (įH 1.24 to 1.30), 
hydroxyl-bound CH (įH 3.00 and 4.50), and the CH2 group attached to the acid terminus (įH 2.19 to 
2.80) are characteristic of polyhydroxylated saturated fatty acids. The oxymethine protons also 
corresponded to peaks resonating between 60 and 75 ppm as shown by its 
13
C NMR spectrum (see 
Supplementary Information). The presence of two polyhydroxylated saturated fatty acid congeners 
(Figure 3) at a ratio of 1:1 was confirmed by their extracted ion chromatograms (Figure 4). Due to the 
overlapping carbon resonances of the oxymethine, long chain methylene and terminal methyl groups, it 
was not possible to deduce unambiguously the position of the hydroxyl groups by HMBC. MS
n
 
fragmentation in the positive mode revealed the position of the hydroxyl units on the alkyl chain 
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through homolytic bond cleavage as shown in Figures 5 and 6. This was then unambiguously 
supported by the COSY NMR data (Figure 7). The two polyhydroxylated saturated fatty acids were 
then elucidated as 3,6,8,11-tetrahydroxy-16,17-dimethyloctadecanoic acid and 2,8,10,19-tetrahydroxy-18-
methyldocosanoic acid, respectively. When compared to the ca. 34 ppm proton chemical shifts of 
oxymethine hydrogens, the proton resonance of the terminal 2-hydroxybutanoic acid moiety was 
deshielded to 45 pm which was comparable to those of the glykenin antibiotics (Figure 8) [22]. 
Figure 3. Structure of polyhydroxylated saturated fatty acids found in fractions 221230. 
 
Figure 4. Extracted ion chromatograms and high resolution mass spectra of fractions 221230. 
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Figure 5. MS
n
 fragmentation of the polyhydroxylated lipids found in fractions 221230. 
Source fragmentation data in the positive mode summarizing the MS
n
 ion peaks for  
m/z 377.2898 (red) and 419.3668 (blue).  
 
Figure 6. Proposed fragmentation pathway for 3,6,8,11-tetrahydroxy-16,17-dimethylocta 
decanoic acid (C20H40O6) and 2,8,10,19-tetrahydroxy-18-methyldocosanoic acid (C23H46O6). 
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Figure 7. 
1
H-COSY NMR of fractions 221226 and 227230, which were the most potent 
against B. subtilis. (Full spectral data in Supplementary Information). 
 
 
Aside from Streptomyces strain SM8, other species of Streptomyces such as S. scabies primarily 
produce saturated fatty acids rather than unsaturated fatty acids [23]. Hydroxy saturated fatty acids 
have previously been reported to have activity against some strains of fungi [24], whereas other 
saturated fatty acids have been proven to inhibit the growth of methicillin-resistant Staphylococcus 
aureus [25]. Polyhydroxy saturated fatty acids have previously been isolated from fungi such as 
Ulocladium botrytis and Haematomma ventosum [26,27]. They have also been found as degradation 
products of guanidylfungin A and B (Figure 8), metabolites of S. hygroscopicus that are active against 
fungi and Gram-negative bacteria [28,29]. The tetrahydroxy saturated fatty acids also comprise the 
aglycone portion of the deacetyl glykenins AC (Figure 8) which are glycosidic antibiotics produced 
by Basidiomycetes sp. [22]. 
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Figure 8. Structures of the guanidylfungins and deacetyl glykenins. 
 
The active fractions were also analyzed by LC-Orbitrap and based on accurate mass (±3 ppm),  
we searched the Dictionary of Natural Products (DNP) database to putatively identify metabolites that 
had previously been reported as products of Streptomyces sp. As seen in Table 3, the predominant 
identified compounds were members of the antimycin family.  
Table 3. Streptomyces metabolites dereplicated from active fractions using the DNP 2012 
database. Metabolites in this table are limited to those with the largest peak area and from 
the biological source Streptomyces sp. Kitamycin also belongs to the antimycin family of 
antifungal compounds. 
Fraction  m/z RT (min) Name Formula 
221226 
[M + H]+ 465.2235 19.53 Kitamycin A or B C23H32N2O8
[M í H]í 519.2353 19.43 Antimycin A3 or A7 C26H36N2O9
227230 
[M + H]+ 535.2652 20.70 
Antimycin A2, A8, A11 or A17 C27H38N2O9 
[M í H]í 533.2512 20.67 
239242 
[M + H]+ 521.2493 24.34 
Antimycin A3 or A7 C26H36N2O9 
[M í H]í 519.2352 24.25 
243248 
[M + H]+ 535.2650 25.63 Antimycin A2, A8, A11 or A17 C27H38N2O9
[M í H]í 519.2352 24.25 Antimycin A3 or A7 C26H36N2O9
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2.2.2. Deletion of Antimycin Gene Cluster from Streptomyces Strain SM8 
Genomic analysis of Streptomyces strain SM8 revealed the presence of an antimycin biosynthetic 
gene cluster with high similarity to and the same gene organization as that identified from 
Streptomyces albus S4 [18]. In order to determine the contribution of antimycin to the total antifungal 
activity of the strain this gene cluster was inactivated. The antC gene, encoding a NRPS central to the 
antimycin biosynthesis pathway, was deleted from the strain (Figure 9). The deletion in the resulting 
strain, SM8-ǻantC, was confirmed by PCR. 
Figure 9. Disruption of antimycin biosynthesis cluster in Streptomyces strain SM8 by 
deletion of antC. Panel A: Characterized antimycin gene cluster containing genes antA to 
antO. Genes are color coded according to predicted roles in pathway; regulationred; 
NRPS and PKS scaffold biosynthesisgreen; FSA starter unit biosynthesisblue;  
post-PKS/NRPS tailoringpink; PKS extender unit supplygrey. The antC gene encodes 
an NRPS gene essential for antimycin biosynthesis. To disrupt the antimycin gene cluster 
regions from upstream and downstream of the antC gene (shown underlined) were PCR 
amplified and cloned into the vector pKC1139 to produce pKC1139A1A2. This plasmid 
was introduced into Streptomyces strain SM8 in order to delete the antC gene as described; 
Panel B: antimycin gene cluster following deletion of a 3 kb part of the antC gene;  
Panel C: Antifungal bioassay of antC mutant strain. Antifungal activities of a dilution 
series of extracts (rows 14) were determined against C. albicans; 1WT extract grown in 
OM-SW broth; 2ǻantC extract grown in OM-SW broth; 3WT extract from SYP-SW 
broth; 4ǻantC extract from SYP-SW; column Gno extract; column Sno inoculum. 
 
Both the mutant (SM8-ǻantC) and wild-type SM8 were cultured on OM-SW and SYP-SW and the 
resulting extracts were subjected to bioassays. Extracts from the SM8-ǻantC mutant strain were shown 
to have ~32-fold less antifungal activity than the wild-type SM8 (Figure 9). LC-Orbitrap analysis of 
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the culture extracts in comparison to an antimycin A standard mixture (Sigma, St. Louis, MO, USA) 
confirmed the presence of antimycins A1, A2, A3 and A4 in the wild-type but not in the mutant SM8 
strain (Figure 10). Although the datasheet of Sigma-Aldrich (St. Louis, MO, USA) claimed it only 
contains antimycins A1A4, A5 and A6 were also seen in the LC-MS. The OM-WT extract contained 
compounds with the same m/z and retention time as the standard, as evidenced in Figure 10, in addition 
to other compounds that had the same m/z but different retention times. It is likely that these are 
additional isomers of antimycin, not present in the standard, as the majority of these contain the 
fragment ion at m/z 265.081 [M + H]+, which is characteristic of the antimycins. The SYP-WT extract 
did not contain any antimycin compounds that were identical to those present in the standard; however 
compounds identical to the putative additional antimycins present in the OM-WT extract were detected. 
The extracts from the SM8-ǻantC strain were found to contain no traces of antimycin-like compounds. 
The chromatograms are shown in Figure 10, a summary of the antimycin metabolites identified is 
shown in Table 4, and the structures of antimycins A1A4 together with the fragmentation of the 
dilactone ring of antimycin A1a to generate the fragment ion with an m/z of 265.081 are shown in 
Figure 11. Using a single point calibration assay, total antimycin content can be quantified from the 
summation of peak areas of extracted ion peaks of detected antimycin congeners in comparison to  
1 mg/mL concentration of standard antimycin mixture sample. OM-WT and SYP-WT extract had a 
total antimycin content of 161.61 and 15.10 ȝg/mL, respectively as based on peaks exhibiting a 
fragment ion at m/z 265.081. 
Figure 10. Analyses of antimycin production in wild-type and mutant strains. Extracts 
were analyzed by LC-Orbitrap and compared to the antimycin A standard. Although the 
standard is alleged to contain antimycin A1 to A4, peaks corresponding to antimycin A5 
and A6 were also identified. The samples are as follows: antimycin A standard (dark blue); 
extract from SM8 WT grown in OM-SW (red); extract from SM8-ǻantC mutant grown in 
OM-SW (green); extract from SM8 WT grown in SYP-SW (pink); extract from SM8-ǻantC 
mutant grown in SYP-SW (light blue).  
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Table 4. Identification of antimycins in the SM8 extracts. Compounds were identified  
as antimycins based on comparison to authentic antimycin standards (STD). Compounds 
with identical m/z values and based on the presence of the characteristic fragment ion  
at m/z 265.081 [M + H]+ (indicated by +) were putatively identified as antimycins.  
n.d (m/z 265 not detected). 
Antimycin 
A 
m/z  
[M + H]+ 
STD OM WT OM antC SYP WT SYP antC 
RT m/z 265 RT m/z 265 RT m/z 265 RT m/z 265 RT m/z 265 
1 549.280 
  22.54 +  n.d 22.56 +  n.d 
27.92 + 27.95 +  n.d    n.d 
2 535.264 
  19.97 +  n.d 20.90 +  n.d 
  21.26 +  n.d 21.27 +  n.d 
25.61 + 25.23 +  n.d    n.d 
26.58 + 26.58 +  n.d    n.d 
3 521.249 
  19.77 +  n.d 19.65 +  n.d 
23.95 + 23.68 +  n.d    n.d 
25.08 + 25.07 +  n.d    n.d 
4 507.233 23.58 + 23.59 +  n.d    n.d 
5 493.217 22.27 +  n.d  n.d    n.d 
6 479.202 
20.35 +  n.d  n.d    n.d 
20.72 +  n.d  n.d    n.d 
Figure 11. Antimycins A1 to A4. The fragmentation of the ring to generate the 265  
[M + H]
+
 ion, common to antimycins A1a/b to A4a/b, is also shown. 
 
Antimycin R1 R2 
A1a C=OCH(CH3)CH2CH3 (CH2)5CH3 
A1b C=OCH2CH(CH3)2 (CH2)5CH3 
A2a C=OCH(CH3)2 (CH2)5CH3 
A2b C=OCH2CH2CH3 (CH2)5CH3 
A3a C=OCH(CH3)CH2CH3 (CH2)3CH3 
A3b C=OCH2CH(CH3)2 (CH2)3CH3 
A4a C=OCH(CH3)2 (CH2)3CH3 
A4b C=OCH2CH2CH3 (CH2)3CH3 
Deisovaleryl antimycin A3 H (CH2)3CH3 
A5 C=OCH2CH(CH3)2 CH2CH3 
A6 C=OCH2CH2CH3 CH2CH3 
Antimycin A was first isolated from an unknown soil Streptomyces sp. [30]. It was discovered to be 
a mixture of four components, named A1 to A4, which were then purified and characterized. 
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Antimycin A3 was found to be the most active component [31,32] although this appears to be due to 
its diffusion coefficient in agar [33]. Since then, many other compounds falling under the antimycin A 
family have been isolated from other Streptomyces species [34]. These compounds possess antifungal 
activity and act by blocking the electron transport chain via inhibition of the cytochrome bc1 complex. 
Gram positive bacteria lack this antimycin sensitive site and hence are unaffected by antimycin A [35]. 
In the course of this study it was noted that the antC mutant strain had reduced antibacterial activity 
against P. aeruginosa PAO1, but not against any of the other bacterial strains tested. This was 
investigated further and it was discovered that the purified antimycin standard mixture had a 
previously unreported activity antibacterial activity against P. aeruginosa PAO1 with an MIC of  
0.05 mg·mL
í1
. Aside from being a well-known antifungal, antimycin A is also a fish toxicant [36], and 
therefore could be of value to a sponge when produced by an endosymbiont. 
The optimum conditions for antimycin production have previously been studied in S. antibioticus. 
Antimycin production in S. antibioticus has been shown to increase when the tryptophan concentration 
in the media was increased to 2 mg·mL
í1
 after which there was decreased antimycin production. It has 
been proven that the benzene ring of DL-tryptophan is incorporated into antimycin A [37]. More recent 
studies have shown that tryptophan is the precursor from which the 3-formamidosalicylic acid (FSA) 
moiety is formed. The dilactone core is then created by sequential elongation with threonine and 
pyruvate, followed by cyclization to close the ring [38]. In this study, tryptophan was present in the 
yeast extract that was a component of the SYP-SW media, but to what extent this affected antimycin A 
production in SM8 is unknown. OM-SW media was found to be optimum for antimycin A production, 
however tryptophan was not found in the mass spectrum of the blank oatmeal media. The regulation of 
expression of antimycin gene clusters is complex, involving a pathway specific sigma factor, present in 
the gene cluster (antA) which controls genes for the production of the FSA moiety with as yet 
unknown factors controlling expression of the other biosynthesis genes [39]. While OM-SW media is 
certainly the media of choice for antimycin production, other media, such as SYP-SW may be 
preferred for isolation of antifungal compounds other than the antimycins. These results highlight the 
advantages of using both genomics and metabolomics as complementary techniques. The presence of 
the antimycin biosynthetic gene cluster in the SM8 genome facilitated the identification of these 
compounds in the extracts and metabolomic analyses have demonstrated the differences in the 
production of metabolites depending on the growth conditions used. Future work will correlate gene 
expression and metabolomics data. 
2.2.3. Isolation of Compounds from Large-Scale Cultures of Streptomyces SM8 
A larger scale culture of SM8 grown on oatmeal media was extracted in order to isolate compounds. 
Although the antimycins were not obtained as pure compounds, LC-HRMS data indicated that the 
presence of antimycins in the fractions correlated with antifungal activity. 
Three butenolides (Figure 12) were obtained that had previously been isolated from marine 
Streptomyces sp. [40]. These were identified as 4,10-dihydroxy-10-methyl-dodec-2-en-1,4-olide (1), 
4,11-dihydroxy-10-methyl-dodec-2-en-1,4-olide (2), and 4-hydroxy-10-methyl-11-oxo-dodec-2-en-1, 
4-olide (3). The structures were confirmed using HRESIMS and NMR. 
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Figure 12. Butenolides isolated from SM8 (13) and avenolide, a butenolide produced by 
S. avermitilis. 
 
Butenolide 1 has also been isolated from a Streptomyces sp. cultivated from a Mediterranean sponge 
Tethya sp. and has been proven to have inhibitory activity against Trypanosoma brucei brucei [41]. 
These butenolides were also present in the antifungal fractions, although the antifungal activity can be 
attributed to the antimycins that were likewise present in the fractions as purified fractions of these 
butenolides were found to lack antifungal activity. Some furanones have quorum signaling activity [42] 
and it is possible that these butenolides synthesized by SM8 play a regulatory role. The butenolide 
avenolide (Figure 12) has been shown to have a role in the regulation of antibiotic production in  
S. avermitilis [43]. Butenolides are similar in structure to the Ȗ-butyrolactones, the main differences 
being the position of the side chain, the presence of a double bond in the butenolides, and the presence 
of an alcohol functional group on the Ȗ-butyrolactones. Ȗ-Butyrolactones are common signaling 
molecules in Streptomyces, with analogous functions to N-acyl homoserine lactone (AHL) signaling 
molecules of Gram-negative bacteria [44], and the butenolide avenolide has been shown to interact 
with regulatory proteins that are closely related to those involved in regulation via Ȗ-butyrolactones.  
In the avenolide-producing organism S. avermitilis, a proposed biosynthetic gene cluster was identified 
consisting of a regulatory gene, a cytochrome P450 hydroxylase gene and an acyl-CoA oxidase gene. 
The same arrangement of genes was not present in the SM8 genome, and at present the biosynthetic 
pathway of this class of compounds is unknown. Butenolides have also been isolated from sponges [45] 
and research has shown that furanones may be used by eukaryotic host organisms to interfere with 
prokaryotic signaling, thereby regulating the colonies they play host to [46,47]. 
Volatile butenolides and other furanone derivatives have previously been identified as products of 
antimycin degradation [48] and thus were not found in Streptomyces mutants lacking the antimycin 
gene cluster. The three butenolides isolated from SM8 differed from these degradation products in that, 
unlike the volatile butenolides, they lacked the 2-alkyl group and possessed an alkyl chain ratherthan a 
methyl group on C-4. These compounds evidently arose from a different biosynthetic pathway 
unrelated to the antimycin pathway as their production was not diminished in the ǻantC mutant. 
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2.3. Comparison of Endosymbiont and Host Sponge Metabolic Profiles 
2.3.1. LC-HRESIMS Comparison 
The LC-HRESIMS spectra of the Streptomyces SM8 and H. simulans extracts, both prepared as  
1 mg·mL
í1
 in 70:30 methanol:dichloromethane were processed using a customized version of MZmine 
2.10 [49]. After peak picking, alignment of the peaks allowed the generation of a scatter plot  
(Figure 13) to compare the metabolites present in each extract. Metabolites falling within the diagonal 
are present in approximately the same concentration in both extracts whereas those outside the 
diagonal are more prominent in the sample stated in the corresponding axis. Most antimycin 
compounds were found only in the SM8 extract, which is unsurprising as antimycins are bacterial 
products. However, antimycin A1b was detected in the sponge extract, albeit at a lower intensity than 
in the SM8 extract. Deisovaleryl-antimycin A3 (Figure 11) was found in higher concentrations in the 
sponge extract than the bacterial extract. From our studies it is clear that Streptomyces strain SM8 has 
the capacity to produce different antimycin metabolites in different conditions and it is possible that 
the growth conditions in the sponge favored the production of this particular antimycin. It is also 
possible that the isovaleryl side group is removed from the antimycin as a result of sponge metabolism, 
resulting in the high level of this compound in the H. simulans extract. The butenolides 1 and 2 were 
present in low quantities in the sponge extract, but butenolide 3 was found solely in the SM8 sample. 
Figure 13. Scatter plot comparison of H. simulans (x-axis) and SM8 (y-axis) in the positive 
ionization mode. Metabolites identified as belonging to the antimycin family of compounds 
are highlighted in yellow whereas the isolated butenolides are highlighted in green. 
Although the differences in concentration are to be expected, the presence of common 
metabolites in the extracts confirmed that some metabolites in the H. simulans extract are 
products of its symbiont, SM8.  
 
Dereplication of the other metabolites common to both samples resulted in highlighting compounds 
isolated from a variety of sources, including sponges, bacteria, fungi, algae and other marine 
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invertebrates. Figure 14 shows the expansion of the scatter plot in the ESI positive mode with the focus 
on compounds that are present in both samples and have a peak area greater than 1.0 × 10
5
. No peaks 
with this peak area fell within the diagonal in the ESI negative mode. The metabolites are colored 
according to their source. The identified metabolites falling within the diagonal can be seen in Table 5. 
The majority of these compounds have previously been isolated from Streptomyces sp. Thus, although 
these compounds were not isolated from SM8, the fact that these metabolites are produced by the same 
genus gives credence to their putative identifications. 
Figure 14. Common metabolites in H. simulans (x-axis) and Streptomyces SM8 (y-axis) 
extracts with peak areas >1.0 × 10
5
 in the positive ionization mode. Blue circles are 
unidentified; black circles are metabolites previously isolated from fungi, algae and other 
marine invertebrates; green circles are those previously isolated from sponges and/or 
bacteria; red circles are those isolated from Haliclona sp.  
 
The scatter plot illustrates that there are metabolites which are common between the sponge and its 
endosymbiont. This highlights the relationship between the two organisms; that is, it confirms that 
Streptomyces SM8 is likely to be a true symbiont of H. simulans. Several of the putative compounds in 
Table 5 above are small MW peptides and are possibly produced by one of the NRPS gene clusters 
present in Streptomyces SM8, while the compound with Mol_ID P 9915 (9-(4-aminophenyl)-7-hydroxy-2, 
4,6-trimethyl-9-oxo-non-2-enoic acid) is a truncated version of candicidin that could have arisen as a 
shunt product of the candicidin pathway or as a degradation product. Although a candicidin gene 
cluster was present in Streptomyces SM8, intact candicidin was not detected in any of the culture 
broths. It is possible that some metabolites produced by Streptomyces SM8 are utilized by H. simulans 
for defensive or regulatory purposes; as previously mentioned, antimycins can act as both antifungal 
and fish deterrent compounds, and the butenolides may function as signaling molecules. 
  
Mar. Drugs 2014, 12 3339 
 
 
Table 5. Common metabolites present in the extracts of H. simulans and Streptomyces 
SM8 (positive ionization). The compounds were putatively identified using the AntiMarin 
2012 database. Only those from sponges or bacteria are included in the table. 
Mol_ID m/z RT (min) Formula Name Source 
P_752 295.1649 
4.00 C15H22N2O4 
1328-3; Cyclocarbamide B [B] Streptoverticillium sp. 
P_7321 295.1641 
(2S,3R)-3-Amino-2-hydroxy-1-
phenylbutanoyl-L-valine 
[B] Streptomyces neyagawaensis SL-387 
+ DL-3-amino-3-phenylpropionic 
P_7605 206.0812 6.62 C11H11NO3 
Indole-3-lactic acid 
[B] Streptomyces sp. L083; marine 
Streptomyces sp. 7919 
1-(3-Indolyl)-2,3-dihydroxypropan-1-one [B] Streptomyces violaceus, marine 
1-Hydroxymethyl-7-methoxyisoquinolinol Porifera Haliclona sp 
P_958 243.1338 5.27 C11H18N2O4 
Bicycloamid;  [B] Streptomyces albus Tue 2031 
3,7-Dihydroxy-cis,cis-1,8-nonadiene-1, 
9-dicarboxylic acid diamide 
[B] marine actinomycete B 1758 
 Porifera Asteropus sp. 
P_9915 320.1852 14.93 C18H25NO4 
9-(4-Aminophenyl)-7-hydroxy-2,4, 
6-trimethyl-9-oxo-non-2-enoic acid 
[B] Streptomyces griseus subsp. 
 [B] Streptomyces sp 
2.3.2. GC-MS Comparison 
The ethyl acetate-soluble components of H. simulans and Streptomyces SM8 were compared using 
GC-MS. For dereplication purposes as well as to exhaust all information about the investigated 
extracts, GCMS data also was collected in parallel to those found by LC-HRESIMS. In this case, the 
results can be compared taking advantage of the capability of each ionization technique in relation to 
the chemistry of the compounds being detected. Figure 15 shows the GC-MS chromatograms of the 
two samples. It is evident that the sponge has peaks that elute later from the column. These compounds 
were most likely less volatile and thus require a higher temperature to elute. 
The GC-MS peaks were dereplicated using the online NIST11 library. All those present in the  
H. simulans sample at 1517 min were all detected to be steroids. Through their respective EI (electron 
impact) mass spectrum, identified compounds dereplicated from the library had matching factor  
scores 800 for the SI (similarity index) and RSI (reversed search index) while the (Prob) probability 
score were 70. Although three bioactive steroids were earlier isolated from H. simulans [50], the four 
identified steroids 4, 5, 6, and 7 were not among those previously isolated. This indicated that steroids 
4, 5, 6, and 7 may be present in the sponge in smaller quantities. All four have previously been found in 
marine sources including sponges. The previously isolated steroids had short side chains and were more 
polar; thus they may not be volatile enough to be detected by GC-MS without derivatization. The elution 
capability was also influenced by the structural features such as the number of carbons on the side chain, 
the degree of saturation and location of double bonds in the cyclopentanoperhydrophenanthrene ring 
and/or in the side chain whether their orientation is cis or trans, and the number of methyl groups on 
C-4 [5153]. For example, sterols with an ethyl group on C-24 in the side chain as in stigmasta-5, 
24(28)-dien-3-ol (7) had longer retention times than those with a methyl group as in ergosta-5, 
22-dien-3-ol (6). In addition, sterols with a double bond on C-22 elute earlier as found in cholesta-5, 
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22-dien-3-ol (4) than sterols with no double bonds in the side chain like cholesterol (5). The elution 
order thus observed was: cholesta-5,22-dien-3-ol (4) < cholesterol (5) < ergosta-5,22-dien-3-ol (6) < 
stigmasta-5,24(28)-dien-3-ol (7). 
Figure 15. GC-MS chromatograms of H. simulans (top) and Streptomyces SM8 (bottom). 
 
Figure 16. Metabolites putatively dereplicated from the H. simulans and Streptomyces 
SM8 extracts using the NIST11 GC-MS libraries. 
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In contrast to the sponge, the Streptomyces SM8 extract contained smaller molecules that had 
retention times of 1013 min (Figures 15 and 16). However, the dereplicated hits (8, 9, 10, and 11) 
for the bacterial extracts gave poor matching scores, although the RSI factor were 800, the SI factors 
were ranging between 200 and 600 while the probability scores were less than 30. Among these hits 
were thujaketone (9) and 4-ethyl-5-methyl-heptanamide (11). Thujaketone (9) is commonly obtained 
from plants. Conversely, its carbon skeleton is the same as the side chain of ergosterol [54].  
4-Ethyl-5-methyl-heptanamide (11) has previously been isolated from a terrestrial Streptomyces sp. [55] 
as well as from freshwater green alga [56]. The MS spectrum for this compound, a fatty acid amide, 
contained a peak at m/z 59 that is characteristic of aliphatic primary amides [56]. 
3. Experimental Section 
3.1. Culture of Streptomyces Strain SM8 
Streptomyces strain SM8 was isolated from the marine sponge Haliclona simulans as described 
previously [8]. For preparation of extracts, seed cultures (50 mL broth in 250 mL conical flasks) of 
410-SW broth (modified from [57]) (10 g glucose, 10 g glycerol, 15 g casamino acids, 5 g oatmeal,  
10 g peptone, 5 g yeast extract, 1 g calcium carbonate, 33.3 g Instant Ocean
®
 per liter of dH2O) were 
inoculated with spores and incubated for 7 days at 28 °C with shaking at 200 rpm. These seed cultures 
were used to inoculate production flasks (50 mL broth in 250 mL conical flasks or 800 mL broth in 2 L 
conical flasks) containing OM-SW broth (modified from [55]) (20 g oatmeal, 33.3 g Instant Ocean
®
 
per liter of dH2O) or SYP-SW broth (10 g starch, 4 g yeast extract, 2 g peptone, 33.3 g Instant Ocean
®
 
per liter of dH2O) at a 1:50 dilution and incubated for 12 days at 28 °C in a shaking incubator at  
200 rpm. All extracts were prepared in triplicates. 
3.2. Preparation of Active Crude Extracts of Streptomyces Strain SM8 
A total of 16 L of the culture broth was clarified by centrifugation at 12,000× g for 15 min in a 
Beckmann Coulter Avanti J-26 centrifuge (Pasadena, CA, USA). The supernatant was passed through 
Miracloth (Calbiochem, San Diego, CA, USA) to remove the debris. Initial compound extraction was 
performed by adding 70 g of prewashed amberlite XAD-16 per liter of culture and incubating 
overnight with shaking. The resin was collected by filtration and the extraction was repeated. Active 
compounds were then eluted from the resin using an equal volume of methanol with stirring for 2 h. 
The methanol washing step was repeated several times until the eluate was colorless. The extract was 
then concentrated by evaporation and desalted by liquid-liquid partitioning with ethyl acetate and water. 
The ethyl acetate fraction was then evaporated to dryness. All extracts were prepared in triplicates. 
3.3. Bioassays 
Crude extracts and purified fractions in triplicates were assayed for antimicrobial activity using  
the following indicator strains: Candida albicans SC5314, Candida glabrata CBS138, Saccharomyces 
cerevisiae BY4741, Kluyveromyces marxianus CBS6556, Aspergillus fumigatus Af293, Bacillus subtilis 
IE32, Escherichia coli 12210, Staphylococcus aureus NC000949 and Pseudomonas aeruginosa PA01. 
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Antifungal [58] and antibacterial [59] activities were determined using resazurin based assays 
performed with dilution series of extracts in 96 well microtiter plates. 
3.4. Genomic Sequencing 
3.4.1. Extraction of Genomic DNA 
Streptomyces strain SM8 was grown in SYP-SW broth for three days at 28 °C in a shaker incubator 
at 200 rpm and the genomic DNA was extracted using the cetyltrimethylammonium bromide (CTAB) 
method [60]. DNA was quantified using a NanoDrop spectrophotometer (Thermo Scientific, Bremen, 
Germany) and analyzed by agarose gel electrophoresis. The concentration of the DNA was adjusted to 
200 ng·ȝLí1 for genome sequencing. 
3.4.2. Genome Sequencing and Analyses 
Genomic sequencing was carried out by the Centre for Genomic Research, University of Liverpool. 
The nucleotide sequence was generated from a fragment library using the GS FLX Titanium system 
(Roche 454 Sequencing, Branford, CT, USA) resulting in 229,280 reads and 94,668,678 bp, giving 
approximately 10-fold coverage of the genome. The genome was assembled using the Meta-assembler 
program hosted by Community cyberinfrastructure for Advanced Microbial Ecology Research and 
Analysis (CAMERA 2.0) [61] and the reads were quality filtered resulting in 539 contigs. The genome 
was annotated using the Prodigal pipeline hosted by IMG/ER [62]. Secondary metabolite genes were 
additionally identified using antiSMASH [63] that rapidly identifies a whole range of known 
secondary metabolite compound classes. Contigs identified as containing secondary metabolism genes 
were used as queries to scan for functional similarities both in Clusters of Orthologous Groups of 
proteins (COGs) and Pfam databases in IMG/ER. The IMG/ER has about 88 COG proteins and  
52 Protein families (Pfam) relating to secondary metabolism and synthesis, catabolism and transport. 
The protein sequences corresponding to the secondary metabolite genes were searched in  
BLASTp [64]. The sequences were also compared to other Streptomyces species in the NCBI database 
using BLAST to identify the closest homologue. The genome sequence is deposited at GenBank with 
accession number PRJNA180938. 
3.5. Identification and Isolation of Bioactive Metabolites of SM8 
3.5.1. Reverse Phase MPLC of Small Scale SM8 Extract 
The SM8 extract, weighing 343.7 mg, was subjected to medium pressure liquid chromatography 
(MPLC) using a Sepacore
®
 chromatography system (Büchi Labortechnik, Basel, Switzerland) consisting 
of two C 605 pump modules, a C 620 control unit over a VersaPak C-18 (Spherical) 23 × 53 mm  
(15 g) column. The column was eluted with water (A) and methanol (B) using the following stepwise 
gradient: 1% B (5 min), 1%50% B (30 min), 50% B (5 min), 50%100% B (25 min). The flow rate 
was 10 mL·min
í1
. Fractions were collected every 15 s. A total of 264 fractions were obtained. These 
were pooled according to their LC-MS chromatograms as measured by the low resolution Finnigan 
LCQ-Deca mass spectrometer coupled to an HPLC (series 1100) from Agilent (Santa Clara, CA, USA). 
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3.5.2. NMR and LC-HRESIMS of Active SM8 Fractions 
Following activity assays, the active fractions were analyzed by NMR using a Jeol-LA400  
FT-NMR spectrometer system (JEOL Ltd., Tokyo, Japan) with an AS400 magnet (Oxford Instruments, 
Inghilterra, UK) at 400 MHz for 
1
H and 100 MHz for 
13
C, using a Pulse Field Gradient Autotune 
40TH5AT/FG broadband high sensitivity probe (JEOL Ltd., Tokyo, Japan) to accept 5 mm tubes. 
High-resolution mass spectrometry was carried out on a Dionex UltiMate-3000 (DIONEX, Sunnyvale, 
CA, USA) coupled to an Exactive-Orbitrap (Thermo Scientific, Bremen, Germany). The column was an 
ACE 5 C18 75 × 3.0 mm column from Hichrom Ltd, Reading, UK. Compounds were eluted with a 
flow rate of 300 ȝL·miní1 using water (A) and acetonitrile (B), both of which contained 0.1% formic 
acid, by a gradient starting with 10% B and increasing to 100% B in 30 min. The mobile phase was 
maintained at 100% B for 5 min, after which the column was equilibrated with 10% B. The injection 
volume was 10 ȝL and the tray temperature was maintained at 12 °C. High resolution mass 
spectrometry was carried out in both positive and negative ESI ionization modes with a spray voltage 
of 4.5 kV and capillary temperature of 268 °C. Spray voltage at 4.5 kV, spray current set 10.67 ȝA, 
and capillary voltage at 30 V. The mass range was acquired from m/z 150 to 1500. 
Multi-fragmentation (MS
n
) experiments were accomplished for the positive ionization mode on an 
Orbitrap analyser, CID (The collision-induced dissociation) was utilized with a normalized collision 
energy of 35%, activation Q of 0.250 ms, and activation time of 30.000 ms applied on ions of most 
intense, 2nd most intense, and 3rd most intense peaks for MS2, MS3, and MS4, respectively at an 
isolation width of 3 microns with 5 microscans. Resolution was at 15,000 m/ǻm 50%, while the 
minimum ion signal threshold was set to 500. Fragment mass tolerance for molecular formula 
detection was set to ±5 ppm. 
Data mining was performed using MZmine 2.10 [49]. The following parameters were used: 
The chromatograms were first cropped to 0.538.0 min using the crop filter under the dataset 
filtering function. The centroid mass detector was used for peak detection with the noise level set to 
1.0 × 10
5
 and the MS level set to 1. The chromatogram builder function was set to a minimum time 
span of 0.2 min, minimum height of 1.0 × 10
5
 and m/z tolerance of 0.001 m/z or 5.0 ppm. For 
chromatogram deconvolution the algorithm used was the local minimum search. The chromatographic 
threshold was set to 90.0%. The search minimum in RT range was 0.4 min, minimum relative height 
was 5.0%, minimum absolute height was 3.0 × 10
5
, minimum ratio of peak top/edge was 2 and the 
peak duration range was 0.35.0 min. Isotopes were detected using the isotopic peaks grouper. The  
m/z tolerance was 0.001 m/z or 5.0 ppm, RT tolerance was 0.2 absolute (min), the maximum charge 
was 2 and the representative isotope used was the most intense. Retention time normalization was 
performed using the RT normalizer. Again, m/z tolerance was 0.001 m/z or 5.0 ppm while the RT 
tolerance and the minimum standard intensity were set to 5% (relative) and 5.0 × 10
3
 respectively. The 
peak lists were all aligned using the join aligner (m/z tolerance 0.001 m/z or 5.0 ppm, weight for m/z: 
20, RT tolerance: 5.0% relative, weight for RT: 20). The aligned peak list was gapfilled using the peak 
finder function (intensity tolerance: 1%, m/z tolerance: 0.001 m/z or 5.0 ppm, RT tolerance: 0.5 min). 
An adduct search was performed with the RT tolerance set at 0.2 absolute (min), the m/z tolerance at  
0.001 m/z or 5.0 ppm and the maximum relative adduct peak height at 30%. The adducts searched for 
were Na
+
, K
+
, NH4
+
 and ACN + H. A complex search was also performed using [M + H]
+
 for the ESI 
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positive mode and [M í H]í for the ESI negative mode. The RT tolerance was set at 0.2 absolute 
(min), m/z tolerance was kept at 0.001 m/z or 5.0 ppm, and the maximum complex peak height was set 
at 50%. A custom database search was then performed using the DNP 2012 database [65]. 
3.5.3. Construction of SM8 antC Mutant 
To inactivate the antimycin gene cluster, a two-step gene deletion procedure was used [60]. 
Flanking regions from within the antC gene of approximately 1.4 kb were amplified using the  
High-Fidelity PCR kit (Roche, Basel, Switzerland). Primer pairs (Table 6) were designed to amplify 
upstream and downstream regions with restriction sites engineered suitable for cloning into the 
Streptomyces/E. coli shuttle vector pKC1139 [66]. PCR products from antC1-F/antC1-R and antC2-F/ 
antC2-R were cloned into pJET1.2/blunt using the Fermentas PCR cloning kit. Following sequence 
verification the antC flanking regions were purified as HindIII-XbaI and XbaI-EcoRI fragments, 
respectively and cloned into HindIII and EcoRI digested pKC1139 resulting in pKC1139A1A2. 
Table 6. Primers designed for the construction of the antC deletion strain. Engineered 
restriction sites are shown underlined. 
 Primer Sequences (5ƍ3ƍ) 
antC1-F 
antC1-R 
TATATAAAGCTTGGACGGCTACAGCTACAAGC 
TATATATCTAGAATGAGGTATGCGGTGTCGTA 
antC2-F 
antC2-R 
TATATATCTAGAGAGGTGGTTCGTGGAGGAG 
TATATAGAATTCTGACGATGATGACGTCCTTG 
pKC1139A1A2 was conjugated to Streptomyces sp. SM8 strain. Competent cells of the  
dam-/dcm-E. coli C2925/pUZ8002 were transformed to apramycin resistance with pKC1139A1A2. 
The helper plasmid pUZ8002 can supply transfer functions to oriT-carrying plasmids, such as 
pKC1139. Cultures of E. coli C2925/pUZ8002/pKC1139A1A2 were grown in 10 mL of LB 
containing 25 ȝg kanamycin/mL, 25 ȝg chloramphenicol/mL and 50 ȝg apramycin/mL overnight at  
37 °C. The overnight culture was diluted (1:10) in LB containing the aforementioned antibiotics and 
grown at 37 °C to an OD600 of 0.5. The cells were washed twice with an equal volume of LB to 
remove antibiotics and resuspended in 0.1 vol. of LB. Approximately, 10
8
 spores of the SM8 strain 
were added to 500 ȝL of 2× YT broth (1.6% peptone, 1% yeast extract, and 0.5% NaCl) and subjected 
to heat shock at 50 °C for 10 min, 0.5 mL of E. coli cells were added and the spores were briefly 
mixed. The pellet was resuspended and plated onto MS-SW agar (mannitol 20 g, soya flour 20 g, agar 
20 g, Instant Ocean
®
 33 g made up to 1 L with dH2O). Following incubation at 28 °C for 20 h the 
plates were overlayered with 1 mL antibiotic solution containing 0.5 mg nalidixic acid and 2 mg 
apramycin. These plates were further incubated at 28 °C until potential exconjugants were observed. 
The transconjugants were plated on to SYP-SW media containing nalidixic acid 25 ȝg·mLí1 and 
apramycin 100 ȝg·mLí1 [60] and incubated at 28 °C until exconjugants were observed. 
The shuttle vector pKC1139A1A2 has a (pSG5) temperature-sensitive origin of replication.  
In Streptomyces it can replicate only at temperatures between 28 and 30 °C. When potential 
exconjugants were plated on to SYP-SW containing apramycin 100 ȝg·mgí1 and incubated at 37 °C, 
the vector stops replicating and apramycin resistance is only maintained when the plasmid is integrated 
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onto the chromosome by homologous recombination. Apramycin resistant recombinant clones were 
allowed to sporulate on SYP-SW agar at 37 °C. Spores were collected and plated out to single colonies 
at 28 °C without selection. Single colonies were then picked and screened for the loss of apramycin 
resistance, a phenotype indicating that the plasmid has been lost with deletion of the antC gene. 
The wild-type and mutant SM8 extracts were compared to an antimycin A standard (Antimycin A, 
from Streptomyces sp.) purchased from Sigma-Aldrich Co (St. Louis, MO, USA). The LC-HRMS 
analysis was performed on a Finnigan Surveyor system coupled to a Thermo-Finnigan LTQ Orbitrap 
system using the same column and method stated in section 3.5.2. 
3.5.4. Isolation of Compounds from Large Scale SM8 Culture 
The large-scale SM8 extract, weighing 810.3 mg, was fractionated using a Sephadex
®
 LH20 
column (Pharmacia, Stockholm, Sweden) with methanol as the mobile phase at a flow rate of 1 mL/15 
min (0.067 mL·min
í1
) and a collection volume of 1 mL/test tube. 169 fractions were collected. An 
aliquot of each tube was subjected to activity assays. The active fractions were subsequently pooled 
based on their activity and similarities in the TLC. 
The pooled fraction 127156 displayed prominent antifungal activity. This fraction was further 
purified using a silica column with the following solvent systems: 95:5 hexane:ethyl acetate, 90:10 
hexane:ethyl acetate, 80:20 hexane:ethyl acetate, and 50:50 hexane:ethyl acetate, followed by washing 
of the column with 70:30 dichloromethane:methanol, 50:50 acetone:methanol and 100% methanol. 
The fractions and purified compounds were subsequently subjected to activity assays and analyzed 
using NMR and LC-HRESIMS. 
4,10-Dihydroxy-10-methyl-dodec-2-en-1,4-olide (1): Rf 0.56 (80:20 MeOH:H2O, C-18 silica gel), 
blue-violet with anisaldehyde-sulfuric acid; UVmax 219.0 (MeOH); 
1
H NMR (400 MHz, DMSO)  
į 7.84 (1 H, dd, J = 5.7, 1.4 Hz, H-3), 6.20 (1 H, dd, J = 5.7, 1.8 Hz, H-2), 5.15 (1 H, m, H-4), 1.71 (1 H, 
m, H-5a), 1.55 (1 H, dd, J = 14.3, 6.9 Hz, H-5b), 1.33 (2 H, q, J = 7.5 Hz, H2-11), 1.33 (2 H, H2-6), 
1.28 (brd. s), 0.98 (3 H, s, CH3-13), 0.79 (3 H, t, J = 7.5 Hz, CH3-12); 13C NMR (100 MHz, DMSO)  
į 173.6 (1-C=O), 159.3 (3-CH), 120.8 (2-CH), 83.7 (4-CH), 71.2 (10-C), 41.5 (9-CH2), 34.4 (5-CH2), 
34.4 (11-CH2), 30.1 (7-CH2), 26.9 (13-CH3), 25.0 (6-CH2), 23.8 (8-CH2), 8.8 (12-CH3); HRESIMS: 
Calculated: m/z 227.1602 [M + H]+; Experimental: m/z 227.1637 [M + H]+. 
4,11-Dihydroxy-10-methyl-dodec-2-en-1,4-olide (2): Rf 0.56 (80:20 MeOH:H2O, C-18 silica gel), 
blue-violet with anisaldehyde-sulfuric acid; UVmax 219.0 (MeOH); 
1
H NMR (400 MHz, DMSO)  
į 7.84 (1 H, dd, J = 5.7, 1.4 Hz, H-3), 6.20 (1 H, dd, J = 5.7, 1.8 Hz, H-2), 5.15 (1 H, m, H-4), 3.42 (2 H, 
m, H2-11), 1.71 (1 H, m, H-5a), 1.55 (1 H, dd, J = 14.3, 6.9 Hz, H-5b), 1.33 (2 H, H2-6), 1.28 (brd. s), 
0.96 (3 H, d, J = 6.3 Hz, CH3-12), 0.77 (3 H, td J = 6.6 Hz, CH3-13); 13C NMR (100 MHz, DMSO) į 
173.6 (1-C=O), 159.3 (3-CH), 120.8 (2-CH), 83.7 (4-CH), 70.0 (11-CH2), 41.0 (10-CH), 34.4 (5-CH2), 
32.8 (9-CH2), 30.1 (7-CH2), 27.2 (8-CH2), 25.0 (6-CH2), 19.9 (12-CH3), 15.1 (13-CH3); HRESIMS: 
Calculated: m/z 227.1602 [M + H]+; Experimental: m/z 227.1637 [M + H]+. 
4-Hydroxy-10-methyl-11-oxo-dodec-2-en-1,4-olide (3): UVmax 223.0 (MeOH); 
1
H NMR (400 MHz, 
DMSO) į 7.84 (1 H, d, J = 5.9 Hz, H-3), 6.20 (1 H, dd, J = 5.6, 1.9 Hz, H-2), 5.14 (1 H, dd,  
J = 7.2, 5.1 Hz, H-4), 2.09 (3 H, s, CH3-12), 1.70 (1 H, m, H-5a), 1.55 (1 H, dd, J = 14.9, 7.4 Hz,  
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H-5b), 1.27 (m), 0.98 (3 H, d, J = 6.9 Hz, CH3-13); HRESIMS: Calculated: m/z 225.1446 [M + H]+; 
Experimental: m/z 225.1486 [M + H]+. 
3.6. Comparison of Endosymbiont and Host Sponge Metabolic Profiles 
3.6.1. LC-HRESIMS Analysis of Extracts 
An acetone-methanol extract of H. simulans was de-salted with gradient elution through HP20 
using water and methanol followed by 50:50 acetone:methanol and 100% methanol washes. An aliquot 
was taken from each fraction aside from the 100% water and the 90:10 aliquots, which contained the 
most salt. The pooled aliquot was dried down and resuspended in 10:90 H2O:MeOH to a final 
concentration of 1 mg·mL
í1
 for LC-MS. The SM8 sample was taken from the larger-scale extract and 
was dissolved in methanol. The samples were run on an Accela HPLC system coupled to a Thermo 
Scientific Exactive-Orbitrap using the same column and method stated in section 3.5.2. The results 
were compared using MZmine 2.10 [49]. 
3.6.2. GC-MS Analysis of Extracts 
The ethyl acetate-soluble portions of the extracts of H. simulans and SM8 were run on a Focus  
GC-DSQ II from Thermo Scientific (Thermo Fisher Scientific (Bremen) GmbH, Bremen, Germany). 
The column, InertCap 1MS (ID: 0.25 mm, length: 30 m, df: 0.25 ȝm) was from GL Sciences Inc., 
Tokyo, Japan. The oven temperature was set at 80 °C for 1 min after which the temperature was 
increased at a rate of 15° min
í1
 until 200 °C. This temperature was maintained for 15 min after which 
it was again increased at a rate of 5° min
í1
 until the final temperature of 320 °C. This was held for  
10 min until the end of the run. The base temperature of the SSL was 250 °C whereas the MS transfer 
line was maintained at 320 °C. The electron ionization (EI) source temperature of the DSQ II mass 
spectrometer was set to 250 °C. The injection was performed in the splitless mode with helium as the 
constant carrier gas at a flow rate of 1.5 mL·min
í1
 and mass scan range at m/z 50.0800.0. 
4. Conclusions 
The combined metabolomic and genomic approach used in this study resulted in the rapid 
identification of antimycins and polyhydroxylated saturated fatty acids as major antifungal and 
antibacterial metabolites of Streptomyces SM8, respectively. Bioassay-guided fractionation of large 
scale SM8 extracts also highlighted the presence of the antifungal antimycin family of compounds. 
Three butenolide compounds were also isolated and identified and while the biosynthetic origin  
of these compounds is currently unknown, the genome sequence of Streptomyces SM8 provides  
a genetic framework with which to study their biosynthesis and their potential role in regulation of 
gene expression. Likewise, as the SM8 ǻantC mutant retained some antifungal activity, larger scale 
cultivation of these mutants can lead to the identification of potentially novel antifungal metabolites 
with genomic correlation to secondary metabolism gene clusters. 
Comparison of the extracts of the host sponge H. simulans and its endosymbiont, Streptomyces 
SM8, using high resolution LC-MS revealed the presence of metabolites, including antimycins and a 
putative candicidin shunt or degradation product common to both extracts. This confirmed that SM8 is 
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indeed associated with H. simulans and that bioactive components produced by Streptomyces SM8 are 
present in the sponge tissue, thus providing further evidence of the potential for microbial symbionts to 
provide their sponge host with a chemical defense system. 
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